
CVS Earnings
CVS Health Corp
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of CVS Health Corp(CVS) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of CVS Health Corp earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
FY2025Q1 | 2025-05-01 | Pre-Market | 1.71 | 2.25 | +31.58 | 93.37B | 94.59B | +1.31 | +4.11 | -0.72 |
FY2024Q4 | 2025-02-12 | Pre-Market | 0.89 | 1.19 | +33.71 | 96.88B | 97.71B | +0.85 | +14.95 | +20.73 |
FY2024Q2 | 2024-08-07 | Pre-Market | 1.74 | 1.83 | +5.17 | 91.43B | 91.23B | -0.22 | -3.21 | -4.32 |
FY2024Q1 | 2024-05-01 | - | 1.69 | 1.31 | -22.49 | 89.20B | 88.44B | -0.86 | -16.84 | -17.68 |
FY2023Q4 | 2024-02-07 | - | 2.01 | 2.12 | +5.47 | 90.72B | 93.81B | +3.41 | +3.10 | +3.84 |
FY2023Q3 | 2023-11-01 | - | 2.13 | 2.21 | +3.76 | 88.17B | 89.76B | +1.81 | -0.41 | +1.80 |
FY2023Q2 | 2023-08-02 | - | 2.12 | 2.21 | +4.25 | 86.53B | 88.92B | +2.77 | +3.33 | +0.07 |
- | 2023-05-03 | - | 2.07 | 2.20 | +6.28 | - | - | - | -3.68 | -3.83 |
- | 2023-02-08 | - | 1.92 | 1.99 | +3.65 | - | - | - | +3.47 | +2.95 |
- | 2022-11-02 | - | 1.99 | 2.09 | +5.03 | - | - | - | +2.30 | +7.43 |
CVS Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, CVS Health Corp reported performance for FY2025Q1, announced on 2025-05-01. The company achieved an EPS of 2.25, compared to analyst estimates of 1.71 by 31.58% . Revenue for the quarter reached 94.59B compared to expectations of 93.37B by 1.31% .
The stock price reacted with a 4.11% one-day change and a -0.72% five-day change following the earnings release. These movements reflect market reaction in CVS Health Corp growth trajectory and strategic initiatives.
CVS Earnings Forecast
Looking ahead, CVS Health Corp(CVS) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q2 project quarter revenue of 94.87B and an EPS of 1.45.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Downward by -0.54%, while EPS estimates have been Revise Upward by 3.93%. For the upcoming Q2 2025, revenue estimates have been adjusted Revise Downward by -0.47% . These revisions correlate with a -0.31% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in CVS Health Corp long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between CVS's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Downward

-0.54%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+3.93%
In Past 3 Month
Revenue Estimates for Q2 2025
Revise Downward

-0.47%
In Past 3 Month
Stock Price
Go Down

-0.31%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:387.56B
--
EPS Estimate-Annual FY 2025:6.13
—
Stock Price64.04
CVS Revenue and EPS Performance: A Historical Perspective
CVS Health Corp revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q1 (2025-05-01,Pre-Market):
EPS: 2.25 (Actual) vs.1.71 (Estimate) (31.58%)
Revenue: 94.59B (Actual) vs. 93.37B (Estimate) (1.31%)
Price Reaction: 4.11%(1-Day), -0.72%(5-Day)
FY2024Q4 (2025-02-12,Pre-Market):
EPS: 1.19 (Actual) vs.0.89 (Estimate) (33.71%)
Revenue: 97.71B (Actual) vs. 96.88B (Estimate) (0.85%)
Price Reaction: 14.95%(1-Day), 20.73%(5-Day)
FY2024Q2 (2024-08-07,Pre-Market):
EPS: 1.83 (Actual) vs.1.74 (Estimate) (5.17%)
Revenue: 91.23B (Actual) vs. 91.43B (Estimate) (-0.22%)
Price Reaction: -3.21%(1-Day), -4.32%(5-Day)
Earnings Reaction
The chart below shows how CVS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CVS sees a +0.42% change in stock price 10 days leading up to the earnings, and a -1.46% change 10 days following the report. On the earnings day itself, the stock moves by +0.71%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in MAR/2025, the stock changed -2.87% on the day following the earnings release and then changed by -12.93% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
CVS Health Corp (CVS) Q1 2025 Earnings Call Summary
Positive
2025-05-01
CVS Health's strong financial performance across all segments, including a 7% revenue increase and improved medical benefit ratio, indicates robust operational health. The successful biosimilar market initiative and strategic priorities in digital strategy and cost efficiency further bolster the positive outlook. Despite some concerns about Medicare trends and unclear management responses in the Q&A, the overall sentiment remains positive, with promising projections for 2025 and a substantial dividend return. The lack of a share buyback program is a minor drawback, but the company's financial health and strategic initiatives outweigh these concerns.
CVS Health Corp (CVS) Q4 2024 Earnings Call Summary
Negative
2025-02-13
The earnings call highlights several challenges, including operational issues in Aetna, economic pressures, and increased competition. Despite positive financial performance, the lack of guidance for 2024, potential operating losses, and membership disenrollment in Medicare Advantage are concerning. The Q&A reveals uncertainties in Medicare Advantage trends and management's unclear responses. The absence of share repurchase plans and a high leverage ratio further add to the negative sentiment. These factors, combined with the lack of market cap data, suggest a negative stock price movement over the next two weeks.
CVS Health (CVS) Q3 2024 Earnings Call Summary
Negative
2024-11-06
The earnings call summary and Q&A reveal several concerns: CVS Health faces significant restructuring costs, economic pressures, and long-term profitability issues in healthcare benefits. Despite a 6% revenue increase, adjusted EPS is weak, and there's a notable operating loss in healthcare benefits. The Q&A highlighted disenrollment issues and unclear management responses about the Inflation Reduction Act's impact, adding uncertainty. While there are some positives, like revenue growth in certain segments and a potential PDR reversal, the overall sentiment is negative due to financial and strategic challenges.
CVS Health (CVS) Q2 2024 Earnings Call Summary
Negative
2024-08-07
The earnings call shows mixed financial performance with increased revenues but decreased operating cash flow. The lowered EPS guidance and challenges in the healthcare benefits segment, including a higher medical benefit ratio, create concerns. The Q&A reveals uncertainties, such as potential membership loss in Medicare Advantage and management's lack of clear guidance. Despite returning dividends, the financial health and strategic outlook are concerning, leading to a negative sentiment.
FAQ

What were the key highlights of CVS’s latest earnings report for FY2025Q1?
CVS reported its FY2025Q1 earnings on 2025-05-01, showcasing a revenue of 94.59B against an estimate of 93.37B, resulting in a 1.31% surprise. The EPS was 2.25, surpassing the expected 1.71 by 31.58% . The stock experienced a 4.11% price change on the earnings day and a -0.72% change over the next five days, reflecting market reactions to the results.

How did CVS’s stock price react after the FY2025Q1 earnings release?

What are the revenue and EPS estimates for CVS for 2025/Q2?

How does CVS’s stock price correlate with earnings forecast revisions?

What should investors expect from CVS’s next earnings report?
